ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Psychiatry · JAMA Psychiatry · 2026-09-01

Network meta-analysis of 95 RCTs (5898 antipsychotic-treated patients with schizophrenia spectrum disorders): vs placebo, semaglutide (−10.98 kg), liraglutide (−5.43 kg), topiramate, metformin and exenatide were associated with the largest weight loss (moderate certainty).

Meta-analysisn = 5,898
Stogios et al. Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis
Neurology · Epilepsia · 2026-08-10

In a phase I randomised crossover study of 37 healthy adults, 30-min intravenous topiramate (50–200 mg) showed mean relative bioavailability of 97.1% (90% CI 94.6–99.7%) versus oral topiramate, dose-proportional exposure and no serious adverse events.

RCTn = 37
Bamgboye et al. A Phase I study of the pharmacokinetics (PK), bioavailability, dose proportionality, safety, and tolerability of topiramate injection compared to Oral topiramate in healthy adult participants
Psychiatry · JAMA Psychiatry · 2026-08-01

Individual participant meta-analysis of 12 placebo-controlled trials (2000 people with cocaine or methamphetamine dependence): pooled medications did not significantly improve reduced use (primary) or urine-verified abstinence; 31.2% vs 13.3% achieved each overall.

Meta-analysisn = 2,000
Amin-Esmaeili et al. Evaluating Reduced Use and Abstinence as Outcomes in Pharmacotherapy Trials for Stimulant Use Disorder: A Meta-Analysis of 12 Randomized Controlled Trials

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.